IL112593A0 - Methods for inhibiting bone loss and lowering serum cholesterol - Google Patents

Methods for inhibiting bone loss and lowering serum cholesterol

Info

Publication number: IL112593A0
Authority: IL; Israel
Prior art keywords: methods; bone loss; serum cholesterol; inhibiting bone; lowering serum
Prior art date: 1994-03-02

Application number

IL11259395A

Other languages

English (en)

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-02

Filing date

1995-02-09

Publication date

1995-05-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22760425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL112593(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-09 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1995-05-26 Publication of IL112593A0 publication Critical patent/IL112593A0/xx

Links

206010065687 Bone loss Diseases 0.000 title 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL11259395A 1994-03-02 1995-02-09 Methods for inhibiting bone loss and lowering serum cholesterol IL112593A0 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/205,012 US5478847A (en)	1994-03-02	1994-03-02	Methods of use for inhibiting bone loss and lowering serum cholesterol

Publications (1)

Publication Number	Publication Date
IL112593A0 true IL112593A0 (en)	1995-05-26

Family

ID=22760425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11259395A IL112593A0 (en)	1994-03-02	1995-02-09	Methods for inhibiting bone loss and lowering serum cholesterol

Country Status (23)

Country	Link
US (5)	US5478847A (ja)
EP (1)	EP0674903A1 (ja)
JP (3)	JP2818384B2 (ja)
KR (1)	KR950031069A (ja)
CN (1)	CN1119530A (ja)
AU (1)	AU702575B2 (ja)
BR (1)	BR9500784A (ja)
CA (1)	CA2141999A1 (ja)
CO (1)	CO4340681A1 (ja)
CZ (1)	CZ31395A3 (ja)
HU (1)	HUT72638A (ja)
IL (1)	IL112593A0 (ja)
MY (1)	MY130157A (ja)
NO (1)	NO950774L (ja)
NZ (2)	NZ270460A (ja)
PE (1)	PE44895A1 (ja)
PH (1)	PH31420A (ja)
PL (1)	PL307463A1 (ja)
RU (2)	RU2100024C1 (ja)
SG (1)	SG46354A1 (ja)
UA (1)	UA32636C2 (ja)
YU (1)	YU13695A (ja)
ZA (1)	ZA95976B (ja)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
USRE38968E1 (en) *	1992-07-28	2006-02-07	Eli Lilly And Company	Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en)	1992-07-28	2006-03-28	Eli Lilly And Company	Methods for inhibiting bone loss
TW366342B (en) *	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5847007A (en)	1993-05-13	1998-12-08	Neorx Corporation	Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5770609A (en)	1993-01-28	1998-06-23	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6251920B1 (en)	1993-05-13	2001-06-26	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6319914B1 (en)	1993-11-05	2001-11-20	Apollo Biopharmaceuticals, Inc.	Cytoprotective effect of polycyclic phenolic compounds
US5554601A (en) *	1993-11-05	1996-09-10	University Of Florida	Methods for neuroprotection
US5478847A (en)	1994-03-02	1995-12-26	Eli Lilly And Company	Methods of use for inhibiting bone loss and lowering serum cholesterol
US5512583A (en) *	1995-01-30	1996-04-30	Eli Lilly And Company	Methods of decreasing serum calcium levels
US5856340A (en)	1995-02-28	1999-01-05	Eli Lilly And Company	Method of treating estrogen dependent cancers
CA2223595C (en)	1995-06-07	2008-08-05	Neorx Corporation	Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5726168A (en) *	1995-10-12	1998-03-10	Eli Lilly And Company	Lipophilic benzothiophenes
US6458811B1 (en)	1996-03-26	2002-10-01	Eli Lilly And Company	Benzothiophenes formulations containing same and methods
EA001257B1 (ru) *	1996-03-26	2000-12-25	Эли Лилли Энд Компани	Бензотиофены, содержащие их фармацевтические композиции и способы лечения патологических состояний с их использованием
US5888963A (en) *	1996-04-18	1999-03-30	Auckland Uniservices Limited	Treatment of bone disorders with adrenomedullin
US6440421B1 (en)	1996-04-18	2002-08-27	Auchkland Uniservices Limited	Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5747509A (en) *	1996-06-03	1998-05-05	Schering Aktiengesellschaft	Method for lowering plasma levels of lipoprotein(a)
WO1997048694A1 (en) *	1996-06-20	1997-12-24	Board Of Regents, The University Of Texas System	Compounds and methods for providing pharmacologically active preparations and uses thereof
KR100522646B1 (ko) *	1996-10-30	2005-12-21	일라이 릴리 앤드 캄파니	유방암의예방방법
KR19980033284A (ko) *	1996-10-30	1998-07-25	피터지.스트링거	개선된 유방암 예방법
CA2219377A1 (en)	1996-10-30	1998-04-30	Eli Lilly And Company	Improvements in or relating to the prophylaxis of breast cancer
GB9624800D0 (en) *	1996-11-29	1997-01-15	Lilly Co Eli	Methods of preventing breast cancer
US6069175A (en) *	1996-11-15	2000-05-30	Pfizer Inc.	Estrogen agonist/antagonists treatment of atherosclerosis
DE69836689D1 (de)	1997-09-26	2007-02-01	Auckland Uniservices Ltd	Verwendung von Amylin, Adrenomedullin und deren Analoga zur Behandlung von Knorpeldefekten
US6096781A (en) *	1997-11-14	2000-08-01	Eli Lilly And Company	2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6054446A (en)	1997-12-24	2000-04-25	Sri International	Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EA003328B1 (ru) *	1998-04-08	2003-04-24	Эли Лилли Энд Компани	Легочная и назальная доставка ралоксифена
US20040176470A1 (en) *	1998-05-07	2004-09-09	Steiner Mitchell S.	Method for treatment and chemoprevention of prostate cancer
US7005428B1 (en)	1998-06-11	2006-02-28	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en)	1998-06-11	2002-10-15	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6258826B1 (en)	1998-10-13	2001-07-10	Eli Lilly And Company	Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
CN1250563C (zh)	1999-05-04	2006-04-12	斯特拉坎有限公司	雄激素糖苷及其产生雄性征的活性
US6326365B1 (en)	1999-07-20	2001-12-04	Apollo Biopharmaceutics, Inc.	Methods of prevention and treatment of ischemic damage
US6339078B1 (en)	1999-07-20	2002-01-15	University Of Florida Research Foundation, Inc.	Methods of prevention and treatment of ischemic damage
US20020013327A1 (en) *	2000-04-18	2002-01-31	Lee Andrew G.	Compositions and methods for treating female sexual dysfunction
AR029538A1 (es) *	2000-07-06	2003-07-02	Wyeth Corp	Composiciones farmaceuticas de agentes estrogenicos
DE60106293T2 (de) *	2000-10-25	2005-11-17	Eli Lilly And Co., Indianapolis	Verfahren zur inhibierung von katarakten
US6599921B2 (en)	2001-02-22	2003-07-29	Nanodesign, Inc.	Non-steroidal estrogen receptor ligands
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
EP1312363A1 (en) *	2001-09-28	2003-05-21	Pfizer Products Inc.	Methods of treatment and kits comprising a growth hormone secretagogue
EP2316468A1 (en)	2002-02-22	2011-05-04	Shire LLC	Delivery system and methods for protecting and administering dextroamphetamine
US7342884B2 (en) *	2002-03-13	2008-03-11	Harmonic, Inc.	Method and apparatus for one directional communications in bidirectional communications channel
JP3887588B2 (ja) *	2002-08-30	2007-02-28	株式会社リガク	Ｘ線回折による応力測定法
EP1832583A1 (en)	2002-09-30	2007-09-12	A/S GEA Farmaceutisk Fabrik	Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these
US20060106010A1 (en) *	2003-05-27	2006-05-18	Black Larry J	Methods for inhibiting bone loss
CA2539361A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
US20070191319A1 (en) *	2003-12-17	2007-08-16	Pfizer Inc.	Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US20050137264A1 (en) *	2003-12-22	2005-06-23	Patel Ashish A.	Modafinil compositions
US20050203086A1 (en) *	2004-03-04	2005-09-15	Pfizer Inc.	Methods of treatment using an EP2 selective receptor agonist
MXPA06011686A (es) *	2004-04-08	2006-12-14	Wyeth Corp	Ascorbato de bazedoxifeno como modulador del receptor de estrogeno selectivo.
BRPI0509381A (pt) *	2004-04-08	2007-09-18	Wyeth Corp	dispersão sólida, métodos de preparar a dispersão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência ou o excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal de tecidos endometrais, de tratar cáncer de mamas de um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, composição, forma de dosagem, e, uso de uma dispersão sólida
US20060068010A1 (en) *	2004-09-30	2006-03-30	Stephen Turner	Method for improving the bioavailability of orally delivered therapeutics
US8367105B2 (en) *	2004-11-10	2013-02-05	Teva Pharmaceutical Industries, Ltd.	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
DE602004007302T2 (de) *	2004-11-10	2008-03-20	Teva Pharmaceutical Industries Ltd.	Verfahren zur herstellung von komprimierten festen dosierungsformen, das gut zur verwendung mit schlecht wasserlöslichen arzneistoffen geeignet ist, und danach hergestellte komprimierte feste dosierungsformen
UA89513C2 (uk) *	2004-12-03	2010-02-10	Элан Фарма Интернешнл Лтд.	Стабільна композиція з наночастинок ралоксифену гідрохлориду
US7605269B2 (en) *	2005-03-23	2009-10-20	Actelion Pharmaceuticals Ltd.	Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
US20060270641A1 (en) *	2005-05-31	2006-11-30	Steiner Mitchell S	Method for chemoprevention of prostate cancer
EP2271320A4 (en) *	2008-04-02	2011-05-18	Reddys Lab Ltd Dr	PHARMACEUTICAL RALOXIFY FORMULATIONS
WO2011000581A2 (en)	2009-07-02	2011-01-06	Synthon B.V.	Raloxifene composition
US8501690B2 (en)	2010-04-30	2013-08-06	John G. Stark	Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
JP5508311B2 (ja) *	2011-02-28	2014-05-28	テバファーマシューティカルインダストリーズリミティド	低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態
EP2791128A4 (en)	2011-12-16	2015-04-22	Olema Pharmaceuticals Inc	NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
WO2014203129A1 (en)	2013-06-19	2014-12-24	Olema Pharmaceuticals, Inc.	Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en)	2013-06-19	2014-12-24	Olema Pharmaceuticals, Inc.	Substituted benzopyran compounds, compositions and uses thereof
KR20240142622A (ko)	2015-10-01	2024-09-30	올레마 파마슈티컬스 인코포레이티드	테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
LT3386500T (lt)	2015-12-09	2022-12-27	The Board Of Trustees Of The University Of Illinois	Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
ES2990061T3 (es)	2016-05-10	2024-11-28	C4 Therapeutics Inc	Degronímeros espirocíclicos para la degradación de proteínas diana
CN109790143A (zh)	2016-05-10	2019-05-21	C4医药公司	用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (en)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
RU2019102647A (ru)	2016-07-01	2020-08-03	Г1 Терапьютикс, Инк.	Антипролиферационные средства на основе пиримидина
WO2018081168A2 (en)	2016-10-24	2018-05-03	The Board Of Trustees Of The University Of Illinois	Benzothiophene-based selective mixed estrogen receptor downregulators
MX2019008158A (es)	2017-01-06	2019-12-09	G1 Therapeutics Inc	Terapia de combinacion para el tratamiento del cancer.
KR20190117582A (ko)	2017-02-10	2019-10-16	쥐원 쎄라퓨틱스, 인크.	벤조티오펜 에스트로겐 수용체 조정제
CN110769822A (zh)	2017-06-20	2020-02-07	C4医药公司	用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019006393A1 (en)	2017-06-29	2019-01-03	G1 Therapeutics, Inc.	Morphic forms of git38 and methods of manufacture thereof
CN120698983A (zh)	2018-12-20	2025-09-26	C4医药公司	靶向蛋白降解
KR20220034129A (ko)	2019-07-07	2022-03-17	올레마 파마슈티컬스 인코포레이티드	에스트로겐 수용체 길항제 요법
KR20220119415A (ko)	2019-12-20	2022-08-29	씨4 테라퓨틱스, 인코포레이티드	Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
TW202146412A (zh)	2020-03-05	2021-12-16	美商Ｃ４醫藥公司	用於標靶降解brd9之化合物
IL300397A (en)	2020-08-05	2023-04-01	C4 Therapeutics Inc	Compounds for targeted knockdown of RET
MX2023014059A (es)	2021-06-08	2024-03-12	C4 Therapeutics Inc	Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
WO2024030968A1 (en)	2022-08-03	2024-02-08	Brystol-Myers Squibb Company	Compounds for modulating ret protein
WO2024097980A1 (en)	2022-11-04	2024-05-10	Bristol-Myers Squibb Company	Ret-ldd protein inhibitors
EP4611901A1 (en)	2022-11-04	2025-09-10	Bristol-Myers Squibb Company	Ret-ldd protein degraders
EP4735452A2 (en)	2023-06-30	2026-05-06	Merck Patent GmbH	Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4185108A (en)	1977-05-10	1980-01-22	Westwood Pharmaceuticals Inc.	Antiosteoporotic agents
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) *	1981-04-03	1983-04-19	Eli Lilly And Company	Synthesis of acylated benzothiophenes
IL65379A0 (en)	1981-04-03	1982-05-31	Lilly Co Eli	Process for preparing acylated benzothiophenes
GB2097788B (en)	1981-04-03	1985-04-24	Lilly Co Eli	Benzothiophene compounds and process for preparing them
EP0068563A3 (en)	1981-06-23	1983-06-15	THE PROCTER & GAMBLE COMPANY	Heterocyclic acetic acid compounds and compositions for treating bone diseases
US4729999A (en)	1984-10-12	1988-03-08	Bcm Technologies	Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en)	1987-03-20	1990-11-13	Yale University	Use of clomiphene to increase bone mass in premenopausal women
US5075321A (en) *	1987-03-24	1991-12-24	University Of Pennsylvania	Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en)	1988-10-31	1995-03-07	Endorecherche Inc.	Anti-estrogenic compounds and compositions
US5208031A (en)	1989-06-06	1993-05-04	Kelly Patrick D	Sexual lubricants containing zinc as an anti-viral agent
US5011853A (en)	1989-08-25	1991-04-30	Washington University	Compounds for treatment of cholinergic neurotoxins
US5118667A (en)	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
DE4122484A1 (de) *	1991-07-06	1993-01-07	Teves Gmbh Alfred	Schaltungsanordnung zur erkennung von radsensordefekten
DE4123368C1 (ja)	1991-07-15	1992-11-05	Bergwerksverband Gmbh, 4300 Essen, De
JP3157882B2 (ja) *	1991-11-15	2001-04-16	帝国臓器製薬株式会社	新規なベンゾチオフエン誘導体
WO1993011074A1 (en) *	1991-11-25	1993-06-10	Healthguard, Incorporated	Multistage coaxial encapsulated filter assembly
TW366342B (en)	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en)	1992-12-22	2000-03-01	Lilly Co Eli	New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en)	1993-03-19	1996-01-09	Eli Lilly And Company	Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en)	1993-06-21	1995-08-29	Eli Lilly And Company	Method for screening anti-osteoporosis agents
DE69405491T2 (de)	1993-06-24	1998-02-19	Lilly Co Eli	Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
TW303299B (ja)	1993-07-22	1997-04-21	Lilly Co Eli
US5441947A (en)	1993-08-25	1995-08-15	Eli Lilly And Company	Methods of inhibiting vascular restenosis
US5468773A (en)	1993-08-25	1995-11-21	Eli Lilly And Company	Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5461065A (en)	1993-10-15	1995-10-24	Eli Lilly And Company	Methods for inhibiting endometriosis
US5457116A (en)	1993-10-15	1995-10-10	Eli Lilly And Company	Methods of inhibiting uterine fibrosis
ZA949715B (en)	1993-12-14	1996-06-06	Lilly Co Eli	Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
US5462949A (en)	1993-12-21	1995-10-31	Eli Lilly And Company	Methods of inhibiting fertility in women
US5591753A (en)	1994-01-28	1997-01-07	Eli Lilly And Company	Combination treatment for osteoporosis
US5811120A (en)	1994-03-02	1998-09-22	Eli Lilly And Company	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5478847A (en) *	1994-03-02	1995-12-26	Eli Lilly And Company	Methods of use for inhibiting bone loss and lowering serum cholesterol
US5972383A (en)	1994-03-02	1999-10-26	Eli Lilly And Company	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
CO4410190A1 (es)	1994-09-19	1997-01-09	Lilly Co Eli	3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en)	1994-09-19	1997-05-13	Eli Lilly And Company	Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US6458811B1 (en)	1996-03-26	2002-10-01	Eli Lilly And Company	Benzothiophenes formulations containing same and methods
US6713494B1 (en)	1996-08-28	2004-03-30	Eli Lilly And Company	Amorphous benzothiophenes, methods of preparation and methods of use
US6096781A (en)	1997-11-14	2000-08-01	Eli Lilly And Company	2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
ID24978A (id)	1997-11-14	2000-08-31	Lilly Co Eli	2-ARYL-3-AROYLBENZO (b) THIOPHENES BERGUNA UNTUK PENGOBATAN SINDROM DEPRIVASI ESTROGEN
US6258826B1 (en)	1998-10-13	2001-07-10	Eli Lilly And Company	Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome

1994
- 1994-03-02 US US08/205,012 patent/US5478847A/en not_active Ceased
1995
- 1995-01-10 SG SG1996003344A patent/SG46354A1/en unknown
- 1995-02-07 CZ CZ95313A patent/CZ31395A3/cs unknown
- 1995-02-07 NZ NZ270460A patent/NZ270460A/xx unknown
- 1995-02-07 CA CA002141999A patent/CA2141999A1/en not_active Abandoned
- 1995-02-07 PE PE1995261225A patent/PE44895A1/es not_active Application Discontinuation
- 1995-02-07 NZ NZ314699A patent/NZ314699A/en unknown
- 1995-02-07 ZA ZA95976A patent/ZA95976B/xx unknown
- 1995-02-09 IL IL11259395A patent/IL112593A0/xx unknown
- 1995-02-10 EP EP95300842A patent/EP0674903A1/en not_active Withdrawn
- 1995-02-14 PH PH49963A patent/PH31420A/en unknown
- 1995-02-16 MY MYPI95000392A patent/MY130157A/en unknown
- 1995-02-27 PL PL95307463A patent/PL307463A1/xx unknown
- 1995-02-28 RU RU95102778/14A patent/RU2100024C1/ru not_active IP Right Cessation
- 1995-02-28 UA UA99116044A patent/UA32636C2/uk unknown
- 1995-02-28 KR KR1019950003983A patent/KR950031069A/ko not_active Ceased
- 1995-02-28 CO CO95007823A patent/CO4340681A1/es unknown
- 1995-02-28 NO NO950774A patent/NO950774L/no not_active Application Discontinuation
- 1995-02-28 RU RU96119781/14A patent/RU2150275C1/ru not_active IP Right Cessation
- 1995-03-01 AU AU13551/95A patent/AU702575B2/en not_active Ceased
- 1995-03-01 HU HU9500634A patent/HUT72638A/hu unknown
- 1995-03-01 YU YU13695A patent/YU13695A/sh unknown
- 1995-03-01 JP JP7041769A patent/JP2818384B2/ja not_active Expired - Fee Related
- 1995-03-01 BR BR9500784A patent/BR9500784A/pt not_active Application Discontinuation
- 1995-03-01 CN CN95100021A patent/CN1119530A/zh active Pending
- 1995-04-14 US US08/422,289 patent/US5610168A/en not_active Expired - Lifetime
- 1995-04-14 US US08/422,417 patent/US5641790A/en not_active Expired - Lifetime
1997
- 1997-01-27 US US08/788,984 patent/US5747510A/en not_active Expired - Lifetime
1998
- 1998-04-17 JP JP10107550A patent/JPH10291932A/ja active Pending
- 1998-04-17 JP JP10107549A patent/JPH10310525A/ja active Pending
2003
- 2003-02-27 US US10/375,274 patent/USRE39050E1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
RU2150275C1 (ru)	2000-06-10
CN1119530A (zh)	1996-04-03
UA32636C2 (uk)	2001-02-15
MY130157A (en)	2007-06-29
RU95102778A (ru)	1996-11-27
JPH07267861A (ja)	1995-10-17
HUT72638A (en)	1996-05-28
US5478847A (en)	1995-12-26
PE44895A1 (es)	1995-12-20
US5641790A (en)	1997-06-24
AU1355195A (en)	1995-09-07
ZA95976B (en)	1996-08-07
JPH10291932A (ja)	1998-11-04
CA2141999A1 (en)	1995-09-03
NZ314699A (en)	2000-07-28
NO950774D0 (no)	1995-02-28
KR950031069A (ko)	1995-12-18
JP2818384B2 (ja)	1998-10-30
NZ270460A (en)	1999-07-29
AU702575B2 (en)	1999-02-25
PL307463A1 (en)	1995-09-04
USRE39050E1 (en)	2006-03-28
US5747510A (en)	1998-05-05
SG46354A1 (en)	1998-02-20
NO950774L (no)	1995-09-04
CO4340681A1 (es)	1996-07-30
JPH10310525A (ja)	1998-11-24
PH31420A (en)	1998-10-29
RU2100024C1 (ru)	1997-12-27
BR9500784A (pt)	1995-10-24
YU13695A (sh)	1999-07-28
US5610168A (en)	1997-03-11
HU9500634D0 (en)	1995-04-28
CZ31395A3 (en)	1995-11-15
EP0674903A1 (en)	1995-10-04

Publication	Publication Date	Title
IL112593A0 (en)	1995-05-26	Methods for inhibiting bone loss and lowering serum cholesterol
AU1856997A (en)	1997-08-22	Method for raising hdl cholesterol levels
AU1487995A (en)	1995-11-23	Surgical lift method and apparatus
SG46441A1 (en)	1998-02-20	System and method for conducting cashless transcations
HUP9904009A3 (en)	2001-07-30	Method and novel compounds for use therein
AU3955295A (en)	1996-05-06	Method and device for tissue resection
AU9486298A (en)	1999-04-12	Surgical apparatus and method
AU4329199A (en)	1999-12-20	Can bottom having improved strength and apparatus for making same
GB9520615D0 (en)	1995-12-13	Method of preventing bone loss
HU9402962D0 (en)	1995-02-28	Methods for lowering serum cholesterol
ZA95701B (en)	1996-04-25	Rivets-nails and methods for their implementation
AU3507795A (en)	1996-06-17	Processor system and method for appliances
AU1132895A (en)	1995-08-24	Method and apparatus for suspension smelting
AU3074099A (en)	1999-09-27	Method and composition for lowering low density lipoprotein cholesterol
GB2330217B (en)	2001-02-28	Polarisng panel and method for making same
GB2342927B (en)	2003-05-07	Apparatus and methods for sputtering
EP0799225A4 (en)	1998-03-25	COMPOUNDS AND RELATED METHODS
GB9508546D0 (en)	1995-06-14	Method and composition
GB9002018D0 (en)	1990-03-28	Squalene synthetase inhibitor and method for lowering serum cholesterol
GB9408702D0 (en)	1994-06-22	Surgical apparatus and method
GB9419087D0 (en)	1994-11-09	Method and composition
GB9414888D0 (en)	1994-09-14	Method and composition
GB9604739D0 (en)	1996-05-08	Surgical method
GB9708810D0 (en)	1997-06-25	Milk-shakes and process for making them
GB9817167D0 (en)	1998-10-07	Compositions and methods for treating elevated blood cholesterol